Amsterdam UMC,
Vrije Universiteit Amsterdam,
Pediatric Oncology,
Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology
Esther Hulleman has not added Biography.
If you are Esther Hulleman and would like to personalize this page please email our Author Liaison for assistance.
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis.
Oncotarget Dec, 2010 | Pubmed ID: 21321380
Blood platelets contain tumor-derived RNA biomarkers.
Blood Sep, 2011 | Pubmed ID: 21832279
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Oncotarget Dec, 2011 | Pubmed ID: 22184287
EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival.
Clinical cancer research : an official journal of the American Association for Cancer Research Aug, 2012 | Pubmed ID: 22696229
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.
Neuro-oncology Sep, 2012 | Pubmed ID: 22723427
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Oncotarget Jan, 2014 | Pubmed ID: 24495907
Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.
Scientific reports Jun, 2014 | Pubmed ID: 24919120
A dual program for translation regulation in cellular proliferation and differentiation.
Cell Sep, 2014 | Pubmed ID: 25215487
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Nature medicine Jun, 2015 | Pubmed ID: 25939062
A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.
Oncotarget Jun, 2016 | Pubmed ID: 26967057
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Aug, 2017 | Pubmed ID: 28818988
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies.
Experimental cell research 11, 2017 | Pubmed ID: 28947132
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma.
Oncotarget 09, 2017 | Pubmed ID: 28947983
Signaling pathways and mesenchymal transition in pediatric high-grade glioma.
Cellular and molecular life sciences : CMLS Mar, 2018 | Pubmed ID: 29164272
Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma.
Cell reports 03, 2018 | Pubmed ID: 29562177
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma.
PloS one , 2018 | Pubmed ID: 29621254
MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 11, 2018 | Pubmed ID: 30061363
An efficient method for the transduction of primary pediatric glioma neurospheres.
MethodsX , 2018 | Pubmed ID: 30622915
Preclinical therapeutic targets in diffuse midline glioma.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 05, 2019 | Pubmed ID: 31202081
MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
Neuro-oncology 01, 2020 | Pubmed ID: 31504799
Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
EBioMedicine Dec, 2019 | Pubmed ID: 31735550
Patient-Derived Orthotopic Xenograft Models of Pediatric Brain Tumors: In a Mature Phase or Still in Its Infancy?
Frontiers in oncology , 2019 | Pubmed ID: 31970083
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2020 | Pubmed ID: 32165429
Development of transient radioresistance during fractionated irradiation in vitro.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology Apr, 2020 | Pubmed ID: 32344261
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved